cemiplimab - Robuta Search

https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=36154928 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=36403742 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=39025426 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://hsbiblio.uni-tuebingen.de/xmlui/handle/10900/164426 A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=35268122 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=39381117 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=39057876 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=39523266 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=36614439 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://www.frontiersin.org/journals/nephrology/articles/10.3389/fneph.2022.1129134/full Frontiers | Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney... The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. The funding statement for the K... squamous cell carcinoma for advanced frontiers corrigendum cemiplimab https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma | FDA On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults... fda approves https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=36340086 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=39164331 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?section=contact&qd=36667553 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=39618602 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=34525939 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=38702836 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=38711059 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://scholars.duke.edu/publication/1815840 Scholars@Duke publication: Alirocumab plus cemiplimab in advanced immuno-refractory metastatic... scholars duke publication alirocumab plus https://www.cancer.gov/news-events/cancer-currents-blog/2018/cemiplimab-fda-squamous-cell-carcinoma Cemiplimab Approved for Squamous Cell Skin Cancer - NCI The immunotherapy drug cemiplimab (Libtayo) has been approved by FDA for advanced cutaneous squamous cell carcinoma, a common type of skin cancer. squamous cell skin cancer cemiplimab approved nci https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?section=elg&qd=36264226 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?section=contact&qd=36532942 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN... https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/innovation-at-the-james/clinical-trials/find-a-clinical-trial/a-phase-ii-and-phase-iii-peri-operative-trial-of A Phase II and Phase III Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1... A Phase II and Phase III Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma https://clinicaltrials.med.nyu.edu/cancer/clinicaltrial/1630/phase-12-study-regn5678/?qd=35248298 A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS... New life-saving treatments for Prostate Cancer in clinical trial on A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN...